Navigation Links
Omeros to Present at Needham Healthcare Conference
Date:4/4/2011

SEATTLE, April 4, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the 10th Annual Needham Healthcare Conference taking place in New York City this week.  The presentation is scheduled for Tuesday, April 5, 2011 at 1:20 p.m. Eastern Time.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including three from its PharmacoSurgery™ platform and two from its addiction franchise. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
2. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
3. Omeros Secures $40 Million Committed Equity Financing Facility
4. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
5. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
6. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
7. Omeros Commences Initial Public Offering of Common Stock
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Appoints New Vice President of Clinical Development
10. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
11. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers and ... is a fully 21 CFR Part 11-compliant email client designed to provide product ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... , ... January 19, 2017 , ... FireflySci Inc. is ... rate. The tremendous growth is accounted to two main factors. The first ... the expanding network of vendors supplying FireflySci products all around the world. , 2016 ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
Breaking Biology Technology:
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... 2017  New research undertaken by Fit Small Business ... 1,000 participants were simply asked which office technology had they ... consider standard issue.  Insights on what will be ... from futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):